Home › Stocks › JAZZ US-listed stock · JAZZ
Jazz Pharmaceuticals Plc (JAZZ): trades by Congress and insiders
No trades disclosed in the last 12 months; 6 disclosures on record in all.
Congress trades 012 months
Members trading 012 months
Insider buys / sales 0 / 012 months 6 disclosed buys and sales on record since 5 November 2021. Insider counts are open-market trades only: awards, option exercises and tax withholding are left out.
Members of Congress who traded JAZZ
Last three years, by number of disclosed trades.
Latest disclosures
Disclosed Filed by Type Amount Traded
7 Oct 2025 Bryan Bedford Executive Sale $50K–$100K
10 Sep 2025
13 Aug 2023 Daniel Goldman House · D-NY Sale $15K–$50K
12 Jul 2023
12 Jun 2023 Ro Khanna House · D-CA Sale $1K–$15K
19 May 2023
17 Apr 2023 Daniel Goldman House · D-NY Buy $15K–$50K
6 Mar 2023
24 Feb 2023 Daniel Goldman House · D-NY Sale $1K–$15K
31 Jan 2023
5 Nov 2021 Thomas Suozzi House · D-NY Buy $1K–$15K
19 Oct 2021
Columns are written from public disclosures: House and Senate periodic transaction reports, SEC Form 4, Japan’s EDINET large-holding reports and Taiwan’s insider registers and market data (TWSE, TPEx, MOPS and the central bank, with history from FinMind). Stock pages add SEC 13F fund holdings and company financials, analysts’ figures from Financial Modeling Prep and Finnhub, and lobbying and federal contract records from the Senate and USAspending.gov. Amounts are disclosed as ranges, so the figures are estimates. Nothing here is investment advice.
Home · Features · Columns · Members of Congress · Stocks · Sitemap · RSS feed of the columns · Privacy and security
Follow us on X Bluesky LinkedIn